What is the investment case, and what must be true for it to hold?
The investment case for CollPlant rests on converting paid development work into commercial sales, provided LightSolver advances its LPU from a working prototype into a commercial product. LightSolver secured an initial order for the first 12 months of the engagement, and its work with Boeing is part of a paid, multi-year development program.
CollPlant also continues to run active operations in the regenerative medicine field.
2Risk Factors
Which risks could break the thesis, and what would warn of them?
Commercialization of LightSolver's LPU is a material execution dependency for CollPlant's photonic-computing thesis, and LightSolver is working to move the LPU from a working prototype toward a commercial product.
LightSolver has secured an initial order under the framework agreement that covers the first 12 months of the engagement.
3Product Overview
What does the product do for its buyer, and how is it delivered?
CollPlant's Collink.3D™ 50L gives tissue engineering and drug-screening work a dry, curable bioink built from lyophilized recombinant human type I collagen that has been chemically modified to cure from its dry form. Constructs biofabricated with Collink.3D™ 50L serve as tissue models for drug discovery and screening and for biofabricated tissues and organs.
Within the Collink.3D™ line, Collink.3D™ 50 supports softer hydrogels, while Collink.3D™ 90 supports stiffer constructs.
CollPlant
CollPlant is a regenerative medicine company with products based on recombinant human collagen, such as the Collink.3D bioink platform.